ACIU AC IMMUNE SA

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
EN
09/10/2020

Underlying

ACIUAC IMMUNE SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AC IMMUNE SA

 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune to Present at the Jefferies 2025 London Healthcare Conferenc...

AC Immune to Present at the Jefferies 2025 London Healthcare Conference AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. The fireside chat will take place on November 18, 2025, at 4:30 ...

7h / 20m 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Reports Third Quarter 2025 Financial Results and Provides a ...

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestonesPeer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056) publish...

November 4, 2025 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of ...

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalitiesIncludes immunotherapies and small molecule drugs targeting intracellular proteinopathiesLeadership in groundbreaking early-stage clinical trials reinforces Company’s competencies Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage bi...

October 28, 2025 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

First Characterization of a TDP-43 PET Tracer Published in Nature Comm...

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s diseasesPET imaging of aggregated TDP-43 could facilitate precision medicine in these diseases, whose shared clinical features complicate differentia...

October 24, 2025 1 EN
Free Trial
ACIU AC IMMUNE SA

AC Immune Sa: 1 director

A director at AC Immune Sa sold 45,000 shares at 3.130USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

10/06/25 October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch